---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-032449"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T10:07:30.306677+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio appoints Katie Peng to Board; commercial launch experience from Denali, Genentech

## Summary
- Katie Peng appointed to Board effective July 10, 2023; board size expanded from 8 to 9 directors.
- Ms. Peng received option to purchase 70,200 shares at $3.38/share, vesting over 36 months.
- She serves as Chief Commercial Officer at Denali Therapeutics, previously SVP at Genentech.
- Led launches of OCREVUS (MS), Evrysdi (SMA), and HEMLIBRA (hemophilia A).
- Appointment adds commercial expertise as Adicet advances ADI-001 towards pivotal study.

## SEC filing metadata
- accession: 0000950170-23-032449
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017023032449/0000950170-23-032449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017023032449/acet-20230710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-032449
- JSON: https://secwatch.observer/filing/0000950170-23-032449.json
- Plain text: https://secwatch.observer/filing/0000950170-23-032449.txt

## Key facts
- Executive change
  Katie Peng was appointed as Director at Adicet Bio, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Katie Peng to the Board, effective as of July 10, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017023032449/0000950170-23-032449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.